1st Quarter - Report

INFECTIOUS DISEASES SOCIETY OF AMERICA for INFECTIOUS DISEASES SOCIETY OF AMERICA

Firm
Client
Income
—
Expenses
$110,000
Expense method
C: businesses, Internal Revenue Code section 162(e)

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Reimbursement for outpatient infusion therapy; physician payments; Medicaid and Medicare, including Medicare Prescription Drug Coverage; Average Sales Price; Competitive Acquisition Program; infection control; antimicrobial stewardship; Healthcare Reform

LobbyistCovered position, as disclosed
LISA COX New Government Relations Director
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: Agency for Healthcare Research & Quality (AHRQ); Food & Drug Administration (FDA); Centers For Disease Control & Prevention (CDC); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Natl Institutes of Health (NIH)

Taxation/Internal Revenue Code TAX

Creation of tax credits to incentivize R&D of new antibiotics for serious and life threatening drug-resistant infections; related new rapid diagnostic tests

LobbyistCovered position, as disclosed
LISA COX New Government Relations Director
AMANDA JEZEK V.P. Public Policy & Government Relations

Contacted: Agency for Healthcare Research & Quality (AHRQ); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); SENATE

Health Issues HCR

Infectious diseases (generally, no specific legislation); drug, diagnostics, and vaccine R&D (generally, no specific legislation); antimicrobial resistance (generally, no specific legislation); antimicrobial stewardship (generally, no specific legislation); hospital-acquired infections (generally, no specific legislation); immunizations (generally, no specific legislation); pandemic influenza, public health security and biodefense (generally, no specific legislation); global infectious diseases (generally, no specific legislation); biomedical research (generally, no specific legislation); reauthorization of the Presidents Emergency Plan for AIDS Relief (PEPFAR) (generally, no specific legislation); Lyme diseases and other infectious diseases issues (generally, no specific legislation); Ryan White reauthorization (generally, no specific legislation); Prescription Drug User Fee Act (PDUFA) (generally, no specific legislation);; Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms (DISARM) Act (HR 512); Preventing Antibiotic Resistance Act (PARA) (S.629)

LobbyistCovered position, as disclosed
LISA COX New Government Relations Director
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Natl Institutes of Health (NIH); Agency for Healthcare Research & Quality (AHRQ); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS)

Bills named: S. 629 (115th), H.R. 512 (115th)

Budget/Appropriations BUD

Funding support for the Department of Health and Human Services, Office of the Biomedical Advanced Research and Development Authority, Centers for Disease Control and Prevention, National Institutes of Health, Health Resources and Services Administration, Food and Drug Administration, and global programs for various infectious diseases related issues.

LobbyistCovered position, as disclosed
LISA COX New Government Relations Director
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: SENATE; Health & Human Services, Dept of (HHS); Natl Institutes of Health (NIH); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Agency for Healthcare Research & Quality (AHRQ); Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC)

Medical/Disease Research/Clinical Labs MED

Medical liability; antimicrobial resistance research; infectious diseases product R&D; regulatory science; unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policy to allow HIV+ to HIV+ organ transplants

LobbyistCovered position, as disclosed
LISA COX New Government Relations Director
AMANDA JEZEK V.P. Public Policy & Government Relations
KIMBERLY ANN MILLER HIV Medicine Association Policy Officer

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Agency for Healthcare Research & Quality (AHRQ); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.